ストックスクリーナーアプリを入手
7.24
1.26%
0.09
アフターアワーズ：
7.19
-0.05
-0.69%
前日終値:
$7.15
開ける：
$7.15
24時間の取引高:
162.74K
Relative Volume:
0.99
時価総額：
$139.88M
収益：
-
当期純損益:
$-22.38M
株価収益率:
-5.1348
EPS:
-1.41
ネットキャッシュフロー:
$-15.54M
1週間 パフォーマンス:
+7.42%
1か月 パフォーマンス:
+9.53%
6か月 パフォーマンス:
+9.37%
1年 パフォーマンス:
-0.82%
1日の値動き範囲:
$6.9701
$7.2818
1週間の範囲:
$5.81
$8.00
52週間の値動き範囲:
$4.44
$12.10
Nuvectis Pharma Inc Stock (NVCT) Company Profile
名前
Nuvectis Pharma Inc
セクター
電話
360-837-7232
住所
1 BRIDGE PLAZA, SUITE 275, FORT LEE
NVCT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
7.24 | 139.88M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-07-13 | 開始されました | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc (NVCT) 最新ニュース
Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback - Seeking Alpha
Nuvectis Pharma launches public stock offering - MSN
Nuvectis Pharma prices 2.7M shares at $5.00 in underwritten public offering - MSN
Nuvectis Pharma 2.7M share Spot Secondary priced at $5.00 - MSN
Nuvectis Pharma announces pricing of $13.5M public offering - MSN
Nuvectis Pharma Prices $13.5 Million Public Offering of Shares -February 05, 2025 at 10:52 am EST - Marketscreener.com
Nuvectis Pharma Prices of $13.5 Million Public Offering of Common Stock - citybiz
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock - GlobeNewswire
Nuvectis Secures Critical $13.5M Funding: Major Push for Revolutionary Cancer Drug Development - StockTitan
Nuvectis Pharma launches public stock offering By Investing.com - Investing.com South Africa
Nuvectis Pharma Announces Proposed Public Offering of Common Stock - GlobeNewswire
Nuvectis Pharma's Strategic Funding Move: Key Details on Oncology Pipeline Investment - StockTitan
(NVCT) Trading Signals - Stock Traders Daily
Critical Contrast: Evolus (NASDAQ:EOLS) and Nuvectis Pharma (NASDAQ:NVCT) - Defense World
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Shares Bought by Baldwin Wealth Partners LLC MA - MarketBeat
How To Trade (NVCT) - Stock Traders Daily
Geode Capital Management LLC Has $501,000 Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
(NVCT) Proactive Strategies - Stock Traders Daily
Nuvectis Pharma: Still Flat, Although There May Be A Ground Floor Here - Seeking Alpha
Insiders hold 63% of Nuvectis Pharma, Inc. (NASDAQ:NVCT), and they've been buying recently - Yahoo Finance
(NVCT) Long Term Investment Analysis - Stock Traders Daily
Great week for Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders who have 63% stake and they haven’t stopped buying - Simply Wall St
Nuvectis Pharma CEO Ron Bentsur buys $20,925 in shares By Investing.com - Investing.com Australia
Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Acquires 4,500 Shares - MarketBeat
Nuvectis Pharma CEO Ron Bentsur buys $20,925 in shares - Investing.com
Nuvectis Pharma stock hits 52-week low at $4.44 amid market challenges - Investing.com Australia
Marlio Charles Mosseri Purchases 17,000 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock - MarketBeat
Nuvectis pharma investor Mosseri-Marlio purchases $79,900 in shares By Investing.com - Investing.com
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium - The Manila Times
NVCT Stock Hits 52-Week Low at $4.61 Amid Market Challenges - Investing.com
Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know - MSN
Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - MSN
Nuvectis Pharma stock hits 52-week low at $4.7 amid market challenges - Investing.com Australia
Nuvectis Pharma stock hits 52-week low at $4.7 amid market challenges By Investing.com - Investing.com South Africa
Nuvectis sinks after early-stage data for ovarian cancer therapy - MSN
Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock By Investing.com - Investing.com Australia
Ron Bentsur Buys Handful Of Shares In Nuvectis Pharma - Simply Wall St
Insider Buying: Nuvectis Pharma Inc (NVCT) Chairman & CEO Acquires Shares - GuruFocus.com
Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock - Investing.com
Vitalli ends work on Daewoong asset; Alector’s $50M loan - Endpoints News
Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Buys 20,000 Shares - MarketBeat
Nuvectis pharma chairman buys $98,400 in common stock By Investing.com - Investing.com Canada
Nuvectis pharma chairman buys $98,400 in common stock - Investing.com
Nuvectis Pharma reports data from Phase 1b study of NXP800 - Yahoo Finance
Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort - The Globe and Mail
Nuvectis Pharma Inc (NVCT) 財務データ
収益
当期純利益
現金流量
EPS
0.82%
0.53%
大文字化:
|
ボリューム (24 時間):